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 1. INTRODUCTION 
 
1.1 Drug Delivery Systems 1  
 Drug release systems are the modified dosage forms used to increase the 
therapeutic efficacy and safety of drugs, thereby reducing both the size and number 
of doses administered. 
1.1.1 Ideal drug delivery system: 
• Should deliver drug at a rate dictated by the needs of the body over 
the period of the treatment. 
• Should channel the active entity solely to the site of action. 
1.1.2  Types of Drug delivery systems:  
 Sustained release drug delivery system: Sustained released dosage 
forms are designed to achieve a prolonged therapeutic effect by continuously 
releasing medication over an extended period of time after administration of a single 
dose. In case of injectable dosage forms, this period may vary from day to months. 
In case of orally administrator forms, however this period is measured in hours and 
critically depends on residence time of the dosage form in the gastro intestinal tract. 
Advantages: 
• For drugs having specific window for absorption increased 
bioavailability can be attained by localizing the SRDF in that 
particular region of the GIT. 
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• Constant blood levels achieve desired effect and this effect is 
maintained for an intended period of time. 
• Better management of disease state is achieved by reduction or 
elimination of fluctuation in drug blood levels. 
• Drug susceptible to enzymatic inactivation or by bacterial 
decomposition can be protected by encapsulation in polymer 
system suitable for SR. 
• Controlled release drug delivery system: Oral controlled drug delivery 
system is a delivery system that provides the continuous oral delivery of 
drugs at predictable and reproducible kinetics for a determined delivery 
throughout the course of GI transit. These systems deliver the drug at a 
predetermined rate and /or to a location according to the needs of the 
body and disease states for a definite period of time. 
Advantages: 
• Reduce dosage frequency. 
• Reduce fluctuation in circulating drug level. 
• Increase patient compliance. 
• Avoidance of night time dosing. 
• More uniform effect. 
• Reduction in GI irritation and dose related side effects. 
• Delayed Release Dosage Form: dosage form releases a discrete portion 
of drug at a time or times other than promptly after administration, 
although one portion may be released promptly after administration. 
Example: Enteric coated dosage forms. 
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• Targeted-release drug products: A dosage form that releases drug at or 
near the intended physiologic site of action. Targeted-release dosage 
forms may have either immediate-or extended-release characteristics. 
• Repeat Action Dosage Forms: It is a type of modified release drug 
product that is designed to release one dose or drug initially followed by 
a second dose of drug at a later time. 
• Prolonged Action Dosage Forms: It is designed to release the drug 
slowly and to provide a continuous supply of drug over an extended 
period of time. 
1.2 Pellets4:  
 Pellets can be defined as small, free flowing, spherical or semi-spherical 
solid units intended for oral administration, which are manufactured by the 
agglomeration of fine powders or granules of active ingredient & excipients using 
appropriate processing equipment. 
 Pellets are usually of diameter range 0.5 mm to 1.5 mm. 
1.2.1 Ideal properties of pellets: 
• Spherical shape and smooth surface texture. 
• Particle size should be of range of 0.5 mm to 1.5 mm 
• The quantity of the active ingredient should be maximum so as to 
maintain the pellet size. 
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Fig 1. Pellets 
1.2.2 Advantages: 
• Improved flow properties and ease of packing resulting in uniform 
and reproducible fill weight of tablets and capsules. 
• Improved appearance of products. 
• Improved safety and efficacy of active ingredient. 
• Decreased handling hazards and easier transport. 
• Decreased hygroscopicity. 
• High bulk density. 
• Little abrasion and decreased friability. 
• Uniform size with narrow size distribution. 
• High drug loading capacity without producing extensively large 
particles. 
• When formulated as modified release preparations pellets are less 
susceptible to dose dumping, thus lowering the risk of side effects. 
• Pelletization prevents accumulation of drugs in GIT, which in turn 
prevents GI irritation. 
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• Pellets disperse freely in GIT fluids due to their small size, 
producing larger surface area for drug absorption and also reduce 
peak plasma fluctuations 
• Pelletization is used for taste masking of unpalatable drugs. 
• Separation of incompatible drugs and/or excipients, such 
ingredients can be formed into pellets and delivered in a single dose 
after encapsulation. 
• In chemical industries, pelletization an effective method of 
avoiding powder dust 
1.2.3 Disadvantages: 
• Pellets are rigid and so cannot be easily compressed into tablets. 
• Production of pellets is an expensive process due to requirement of 
highly specialized equipment and trained personnel. 
• The control of production process is difficult (e.g the amount of 
water added and time is critical for the quality of pellets as over 
wetting can occur easily). 
1.2.4 Significance of pellets: 
 Pellets may have varied applications in varied industries. It just requires 
an innovative bend to use it to derive maximum profitability. The smooth surface & 
the uniform size of the pellets allow uniform coating not only for each pellet but also 
from batch to batch. 
• Improved appearance of the products. Coating of pellets can be 
done with different drugs to enable a controlled release rate. 
• In case of immediate Release Products larger surface area of pellets 
enables better distribution. 
 Page 5 
• Chemically incompatible products can be formed into pellets & 
delivered in a single dose by encapsulating them. 
• In the chemical industries it is used to avoid powder dusting. 
• Pellets ensure improved flow properties, and flexibility in 
formulation development and manufacture. 
• The coating material may be colored with a dye material so that the 
beads of different coating thickness will be darker in color and 
distinguishable from those having fewer coats. 
• The thickness of the coat on the pellets dictates the rate at which the 
drug/ contents are released from the coated particles. 
1.2.5 Rationale for pelletization:  
 The use of pellets as a vehicle for drug delivery at a controlled rate has 
recently received significant attention, pellets disperse freely in gastrointestinal tract, 
so they invariably maximize drug absorption, reduce peak plasma fluctuation, and 
minimize potential side effects without appreciably lowering drug bioavailability, 
pellets also reduce variation in gastric emptying rates and overall transit times, 
which is common with single unit regimens, is minimized, high local concentration 
of bioactive agent, which may inherently be irrigative or anaesthetic, can be avoided, 
when formulated as modified release dosage form, pellets are less susceptible to 
dose dumping than the reservoir type single unit formulation, better flow properties, 
narrow particle size distribution, less friable dosage form and uniform packaging. 
1.2.6 Theory of pelletization:  
 It is important to understand the fundamental mechanisms of granule 
formation and growth. Different theories have been postulated related to the 
mechanism of formation and growth of pellets. The most thoroughly studied and 
most classified pelletization   process, which involves a rotating drum, a pan or a 
disc, has been divided into three consecutive regions: 
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• Nucleation 
• Transition 
• Ball growth.  
 However, based on the experiments on the mechanism of pellet 
formation and growth, the following steps were proposed: 
• Nucleation 
• Coalescence 
• Layering 
• Abrasion transfer. 
 
Fig 2. Pellets growth mechanism 
1.2.6.1 Nucleation: 
 Fine powders can readily be formed into agglomerates by the 
introduction of a liquid phase followed by suitable agitation or tumbling. The liquid 
and solid phases are brought into close contact; this allows binding forces to develop 
and bring about agglomeration. Growth of the particles occurs either by collisions 
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and successful adherence of primary feed particles onto which particles collide and 
attachés themselves. This result in pellet growth formation. 
 When two particles come into close contact, the cohesive forces that hold 
the particles together are: 
• Intermolecular attractive forces: these are very short range 
attractions, van-der Walls dispersive forces make the most 
significant contribution. 
• Electrostatic attractive forces: these are almost always present in 
particulate systems. They are produced primarily by inter-particle 
friction. Although these forces are generally less than those 
experienced in other binding mechanisms, the net effect is to hold 
or orient particles in a contact region for sufficiently long for other, 
more dominant mechanism to operate. 
• Liquid bridge modes: these are three physical situations in which 
the amount of liquid present produces cohesive forces between 
particles. The contributing mechanisms are adsorbed liquid layers, 
mobile liquid bridges, and viscous or adhesive binders. 
Oncesufficient liquid is present to produce liquid bridges in an 
assembly of particles, the cohesive strength of the material 
increased. 
 Nucleation is a common stage in all pelletization processes and occurs 
whenever a powder is wetted with liquid. The primary particles are drawn together 
to form three-phase air-water-liquid nuclei and are attached together by liquid 
bridges which are pendulum in nature. 
1.2.6.2 Transition: 
 The growth mechanisms affecting the transition region are coalescence 
and layering. 
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• Coalescence is defined as the formation of large-sized particles by 
random collision of well-formed nuclei, and the mechanism 
requires slight excess moisture on the nuclear surface. 
•  Although the number of nuclei is progressively reduced, the total 
mass of the system remains unchanged during this step. 
• Layering is a slow growth mechanism and involves the successive 
addition of fragments and fines on an already formed nucleus. In 
the layering step, the number of particles remains the same, but the 
total mass in the system increases due to increasing particle size as 
a function of time. 
1.2.6.3 Ball growth: 
 In the ball growth phase the main mechanism affecting the slow growth 
of agglomeration is the abrasion transfer which involves the transfer of materials 
from one granule formed to another without any preference in either direction. The 
particles, however, undergo a continuous change in size as long as the conditions 
that lead to the transfer of material exist. 
1.2.7  Mechanism of action: 
• Enteric coated capsule dissolves and releases coated pellets. 
• The pellets which are resistant to the gastric juice due to the 
polymer coating, are gradually distributed in the stomach. 
• Because of their small size, the pellets pass easily through the 
pylorus. 
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 Fig 3. Mechanism of action 
 The specific milieu of the duodenum with pH levels 6-7, causes the 
enteric-coating to disintegrate, and the active pharmaceutical ingredient is rapidly 
absorbed. 
1.2.8 Pelletization Techniques: 
• Pelletization by extrusion-spheronization 
• Drug layering (dry powder layering & solution and suspension  
layering) 
• Cryo-pelletization 
• Freeze pelletization 
• Globulation 
• Compression 
• Balling 
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1.2.8.1 Solution/Suspension layering: 
 
Fig 4. Coating suspension and solution layering process 
 The Wurster coating process had evolved through elaborate design 
modiﬁcations and tenement into ideal equipment for the manufacture of pellets by 
solution/ suspension layering. The high drying efficiency inherent in quid-bed 
equipment, coupled with the innovative and efficient design features of the Wurster 
process, has allowed the machines to hold center stage in pharmaceutical processing 
technology.  
                 
Fig 5. Fluid bed coater 
 Not only have the manufacture and coating of pellets become routine and 
efficient, but scaling up of the process, which is key to the viability of any 
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processing technique, has proved to be predictable and economically feasible. The 
primary features that distinguish Wurster equipment from other quid-bed equipment 
are the cylindrical partition located in the product chamber and the conﬁguration of 
the air distributor plate, also known as the oriﬁce plate. The latter is congaed to 
allow most of the ﬂuidization or drying air to pass at high velocity around the nozzle 
and through the partition, carrying with it the particles that are being layered on. 
Once the particles exit the partition, they enter the expansion chamber, where the 
velocity of the air is reduced below the entrainment velocity, and the particles fall 
back to the area surrounding the partition (referred to as the down bed).  
 The down bed is kept aerated by the small fraction of air that passes 
through the small holes on the periphery of the oriﬁce plate. The particles in the 
down bed are transported horizontally through the gap between the air distributor 
plate and the partition by suction generated by the high air velocity that prevails 
around the nozzle and immediately below the partition. The volume of air that 
passes through the down bed outside the partition is just enough to generate modest 
particle movement. Because the spray direction is concurrent with particle 
movement, and particle motion is well-organized under optimum conditions, 
uniform layering of drug substances is consistently achieved. Because the partition 
height, that is, the gap between the partition and the oriﬁce plate, controls the rate at 
which the particles enter the spray zone, it is an important variable that needs to be 
optimized for every batch size. For instance, at a given load size and ﬂuidization air 
volume, the partition height can be reduced or increased to provide either a well- 
controlled particle motion that produces the desired pellet movement or a bubbling 
down bed that leads to disorganized particle movement and inefﬁcient process. 
1.2.8.2 Advantages: 
• Innovative processes for coating of products. 
• Film coating; lipid hot melt coating, Coating of granules, pellets, 
tablets. 
• Specific manipulation of the particle surface characteristics, 
Protection of the product against moisture, light, air,. 
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• Specific manipulation of the way in which the particle dissolves the 
decomposition or the release of active ingredients. 
• Process advantages: Uniform, continuous product coating. Aqueous 
or organic coatings can be applied.  
• Coating and drying take place in one machine. In terms of Total 
Containment, the coating process and the filling and emptying of 
the machine can be carried out in complete isolation and without 
product spreading into the environment. 
1.2.8.3 Principle: 
 Principle involved in fluid bed coater is particles are fluidized and the 
coating fluid sprayed on and dried. Small droplets and a low viscosity of the spray 
medium ensure an even product coating. 
1.2.9 Types: 
• Top Spray Coating 
• Bottom Spray Coating (Wurster Coating) 
• Tangential Spray Coating (Rotor Pellet Coating. 
• Top spray coating: 
 This process is used for general coatings right up to enteric coating. With 
top spray coating in the fluid bed (batch and continuous), particles are fluidized in 
the flow of heated air, which is introduced into the product container via a base 
plate. The coating liquid is sprayed into the fluid bed from above against the air flow 
(countercurrent) by means of a nozzle. Drying takes place as the particles continue 
to move upwards in the air flow. Small droplets and a low viscosity of the spray 
medium ensure that the distribution is uniform. Coating in the continuous fluid bed 
is particularly suitable for protective coatings/color coatings where the product 
through put rates are high. 
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 Fig 6. Top spray 
 The product is continuously fed into one side of the machine and is 
transported onwards via the sieve bottom by means of the air flow. Depending on 
the application, the system is sub-divided into preheating zones, spray zones and 
drying zones. The dry, coated particles are continuously extracted. 
Bottom spray coating (Wurster coating): 
 This process is particularly suitable for a controlled release of active 
ingredients. In the Wurster process, a complete sealing of the surface can be 
achieved with a low usage of coating substance. The spray nozzle is fitted in the 
base plate resulting in a spray pattern that is concurrent with the air feed.  
 
Fig 7. Bottom spray 
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 By using a Wurster cylinder and a base plate with different perforations, 
the particles to be coated are accelerated inside the Wurster tube and fed through the 
spray cone concurrently. As the particles continue traveling upwards, they dry and 
fall outside the Wurster tube back towards the base plate. 
 They are guided from the outside back to the inside of the tube where 
they are once again accelerated by the spray. This produces an extremely even film. 
Particles of different sizes are evenly coated. 
Bottom  spray coating (Continuous fluid bed): 
 Particularly suitable for protective coatings/color coatings where the 
product throughput rates are high. The product is continuously fed into one side of 
the machine and is transported onwards via the sieve bottom by means of the air 
flow. Depending on the application, the system is sub-divided into pre-heating 
zones, spray zones and drying zones whereby spraying can take place from below in 
the form of a bottom spray. The dry, coated particles are continuously extracted. 
Tangential spray coating (Rotor pellet coating): 
 Ideal for coatings with high solid content. The product is set into a spiral 
motion by means of a rotating base plate, which has air fed into the powder bed at its 
edge. The spray nozzle is arranged tangentially to the rotor disc and also sprays 
concurrently into the powder bed. Very thick film layers can be applied by means of 
the rotor method. 
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 Fig 8. Tangential spray 
Limitations: 
 The disadvantage of the Wurster process is the inaccessibility of the 
nozzles. If the nozzles are clogged at any time during the layering process, the 
operation has to be interrupted, and the spray guns must be removed for cleaning. 
The problem can be alleviated by screening the formulation or by using a spray gun 
with a bigger nozzle. Another aspect of the process that is challenging when 
multiple nozzles are used is the potential overlap of adjacent spray zones.  
 Although the position of the nozzle is ﬁxed, the spray zone over- lap can 
be minimized using the air cap at the end of the spray gun. 
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 2. LITERATURE REVIEW 
 
1. NS Dey et al11, reviewed that the multiparticulate drug delivery systems 
are especially suitable for achieving controlled or delayed release oral formulations 
with low risk of dose dumping, flexibility of blending to attain different release 
patterns as well as reproducible and short gastric residence time. The release of drug 
from microparticles depends on a variety of factors including the carrier used to 
form the multiparticles and the amount of drug contained in them. Consequently, 
multiparticulate drug delivery systems provide tremendous opportunities for 
designing new controlled and delayed release oral formulations, thus extending the 
frontier of future pharmaceutical development. 
2. HP Patel et al12, formulated multiple unit particle system (MUPS) of 
stabilized ramipril and hydrochlorothiazide pellets which produced better dissolution 
of the system for better bioavailability with improving stability and bioavailability 
of ramipril. More particularly, the present invention was directed for stabilized 
ramipril against decomposition into degradation products, namely ramipril-DKP and 
ramipril-diacid, during formulation and storage conditions. Simple ramipril 
formulation showed 15.15% related impurities after 3-month accelerated stability 
study, which was minimized to 2.07%, related impurities in ramipril pellets after 6 
month accelerated stability study. By making MUPS of ramipril pellets, 
hydrochlorothiazide showed better dissolution (100.4% of ramipril and 97.9% of 
hydrochlorothiazide within 60 min) to produce better bioavailability. So, making 
MUPS containing ramipril pellets with polymer coating and hydrochlorothiazide and 
other excipients showed better stability of ramipril along degradation and synergistic 
effect among hypertension in immediate delivery. 
3. S.Ramu et al 13 reviewed   the potential advantages of multiple unit 
dosage forms (pellets etc.) over the single unit dosage forms (tablets). Pelletization 
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is a novel drug delivery system; a technique which converts fine powder particles 
into pellets. Review deals with the pellet and its various types of pelletization 
techniques like spheronization and extrusion, pelletization by layering, pelletiztion 
by solution layering &direct pelletization. The advantages, disadvantages & various 
applications of above mentioned techniques.spheronization and extrusion 
pelletization by layering are most widely used techniques. The study also deals with 
factors and evaluation of pellets. 
4. Branka Ivic et al 14 developed  diclofenac sodium extended release 
compressed matrix pellets and optimized using Generalized Regression Neural 
Network (GRNN). According to Central Composite Design (CCD), ten formulations 
of diclofenac sodium matrix tablets were prepared. Extended release of diclofenac 
sodium was acomplished using Carbopol® 71G as matrix substance. The process of 
direct pelletisation and subsequently compression of the pellets into MUPS tablets 
was applied in order to investigate a different approach in formulation of matrix 
systems and to achieve more control of the process factors over the principal 
response — the release of the drug. The investigated factors were X1 -the percentage 
of polymer Carbopol® 71 G and X2- crushing strength of the MUPS tablet. In vitro 
dissolution time profiles at 5 different sampling times were chosen as responses. 
Results of drug release studies indicate that drug release rates vary between different 
formulations, with a range of 1 hour to 8 hours of dissolution.  
5. Phale et al 15reviewed the use of Multiunit particulate systems (MUPS) 
in recent years as a controlled drug-delivery method. The current review describes 
the role and selection of excipients, pellet core, coating materials, and compression 
with various cushioning agents. MUPS technology enables firms to achieve the 
desired and therapeutic release with minimal side effects. Thus, MUPS could open a 
new area of research for scientists with many opportunities for the formulation of 
controlled- and delayed-release oral dosage forms. 
6. Manuel Efentakis et al 16 reviewed the compared the release behavior of 
single-unit (tablets, capsules) and multiple-unit (minitablets in capsules) controlled-
release systems of furosemide. The swelling and erosion behaviors of these systems, 
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which contained the swellable hydrophilic polymers sodium alginate (high viscosity) 
and Carbopol 974P, were compared. Swelling and erosion experiments showed a 
high degree of swelling and limited erosion for the Carbopol preparations, whereas 
less swelling but greater erosion was observed for the sodium alginate preparations. 
The sodium alginate preparations were eroded in 6 hours, while Carbopol 
preparations exhibited limited erosion within this period of time. These results 
appeared to be attributed to the physicochemical characteristics of the polymers used 
in this study. Polymer characteristics greatly influenced the release of furosemide 
(model drug) from the formulations prepared and tested. Sodium alginate had a less 
pronounced sustained release effect compared with Carbopol (ie, in 8 hours all 3 
sodium alginate dosage forms displayed complete release of furosemide, while only 
30% of the drug was released from Carbopol dosage forms). Finally, all 3 Carbopol 
dosage forms (single- and multiple-unit) displayed similar release behavior while 
sodium alginate dosage forms displayed a different and more distinctive behavior. 
Mini tablets and tablets showed a greater sustained release effect compared with 
capsules. Evaluation of the release data indicated that the release mechanism for 
sodium alginate formulations may be attributed to erosion/dissolution, while for 
Carbopol it may be attributed mainly to polymer relaxation and diffusion of the drug 
from the polymer surface. 
7. Gaurav Tiwari1 et al 17  prepared glipizide (GPZ) and GPZ-HPC solid 
dispersion (SD) pellets and characterized for drug release mechanisms from a multi-
unit erosion  matrix system for controlled release. Solid dispersion with HPC was 
prepared by co-evaporation method and characterized by Fourier transform infra red 
spectroscopy (FT-IR), scanning electron microscopy (SEM), differential scanning 
calorimetry (DSC), hot-stage microscopy (HSM), x-ray diffraction (XRD), stability 
studies. Release rate of glipizide from solid dispersion was measured by the rotating 
basket method (JP XII). FT-IR study indicated the presence of hydrogen bonding in 
solid dispersion. SEM confirms the amorphous form in solid dispersion. In DSC 
melting peak in solid dispersion shifted slightly to lower temperature with respect to 
drug alone indicated the conversion to amorphous form which was further proved in 
X-ray diffraction. Hot- stage microscopy  SM have demonstrated the ability of 
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melted HPC to dissolve the crystal of GPZ at increasing temperatures. The release 
rate of GPZ from solid dispersion granules was markedly larger than that from GPZ 
powder, and it was larger with a lower HPC molecular weight. The stability study 
showed that SD systems were not significantly different during six month of 
accelerating condition storage.  
8. Phutane P et al 18  formulated microspheres of glipizide were developed 
by the emulsion solvent diffusion-evaporation technique by using the modified 
ethanol,-dichloromethane co-solvent system. The polymer mixture of ethyl cellulose 
and Eudragit® S100 was used in different ratios (1:0, 1:1, 2:3, 1:4 and 0:1) to 
formulate batches F1 to F5. The resulting microspheres were evaluated for particle 
size, densities, flow properties, morphology, recovery yield, drug content, and in 
vitro drug release behavior. The formulated microspheres were discrete, spherical 
with relatively smooth surface, and with good flow properties. Among different 
formulations, the fabricated microspheres of batch F3 had shown the optimum 
percent drug encapsulation of microspheres and the sustained release of the 
Glipizide for about 12 h. Release pattern of Glipizide from microspheres of batch F3 
followed Korsmeyers-Peppas model and zero-order release kinetic model.  
9. Shailesh et al 19 reviewed a drug delivery system that can have the entire 
various active pharmaceutical ingredients in one capsule and can deliver the drug at 
right time and in proper amount according to body’s circadian rhythm. According to 
recent pharmaceutical applications involving pulsatile delivery the multiparticulate 
dosage forms are getting much favor over single unit dosage form because of their 
smaller particle size these systems have capacity for passing through the G.I. tract 
easily, leading to less inter as well as intra subject variability.  
10. N Pandya et al 20 formulated  floating multi particulate systems that 
have been utilized to obtain prolonged and uniform release of drug in the stomach 
for development of once-daily formulations. A controlled-release system designed to 
increase residence time in the stomach without contact with the mucosa was 
achieved through the preparation of floating microspheres by the emulsion solvent 
diffusion technique, using (i) calcium silicate (CS) as porous carrier; (ii) glipizide, 
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an oral hypoglycemic agent; and (iii) Eudragit® S as polymer. The effects of various 
formulations and process variables on the internal and external particle morphology, 
micromeritic properties, in vitro floating behavior, drug loading, and in vitro drug 
release were studied. The microspheres were found to be regular in shape and highly 
porous. The prepared microspheres exhibited prolonged drug release (~8 h) and 
remained buoyant for >10 h. The mean particle size increased and the drug release 
rate decreased at higher polymer concentrations. No significant effect of the stirring 
rate during preparation on drug release was observed. In vitro studies demonstrated 
diffusion-controlled drug release from the microspheres. Microsphere formulation 
CS4, containing 200 mg calcium silicate, showed the best floating ability (88% 
buoyancy) in simulated gastric fluid. The release pattern of glipizide in simulated 
gastric fluid from all floating microspheres followed the Higuchi matrix model and 
the Peppas-Korsmeyer model. 
11.  Pahwa et al 21 prepared the gastroretentive floating multiple-unit drug  
delivery system for glipizide as a model drug for prolongation of gastric residence 
time. Floating microspheres were prepared by ionotropic gelation method using 
polymeric material such as chitosan. D-optimal design was utilized to investigate the 
joint influence of two variables: drug to polymer ratio (X1) and concentration of 
effervescent agent (X2) on the drug entrapment efficiency, percentage buoyancy, 
and cumulative percentage drug release. Particle size and surface morphology of 
prepared microspheres were characterized by optical and scanning electron 
microscopy respectively. Formulated microspheres exhibited prolonged drug release 
and remained buoyant for more than 12 h. 
12.  Nagarjuna Naik R et al 22  formulated and evaluated enteric coated 
multi particulate systems for  Esomeprazole magnesium dihydrate to reduce the 
gastrointestinal tract side effects. The delayed release multiple units were prepared 
by using fluid-bed Wurster technology. These multiple units were prepared by seal 
coating, drug coating and enteric coating and were evaluated for assay, acid 
resistence, drug release, dissolution.   This stud  concluded that Esomeprazole 
magnesium dihydrate could  be prepared by using combination of polymers and  
reduced the GI tract side effects. 
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13.  Anuranjita Kundu et al 23   formulated  norfloxacin as a suitable micro 
particulate system of Norfloxacin for controlled release delivery system by varying 
the alginate concentrations, calcium chloride concentrations and curing time. 
Norfloxacin microbeads were prepared by ionotropic gelation technique. Prepared 
microbeads were evaluated for granulometric studies, micrometric, scanning 
electron microscopy, drug entrapment efficiency, swelling studies and in-vitro 
dissolution studies. The prepared beads were free flowing and white in color. The 
drug loaded beads showed 37.26% to 91.73% drug entrapment, which was found to 
increase with increase in alginate concentration. In vitro drug release study of these 
microbeads indicated controlled release for Norfloxacin 96.19 – 97.83% release 
after 12 hours. From this study it could be concluded that the free flowing 
microbeads of Norfloxacin could be successfully prepared by ionotropic gelation 
technique with high entrapment efficiency and prolonged release characteristics.  
14. K Senthil Kumaran et al 25 formulated    mosapride-controlled release 
beads with the help of the ionotropic gelation method, using sodium alginate 
containing KHCO 3 as the gas-forming agent. The physical characterization of the 
mosapride beads was examined by SEM. The results showed that the shape and 
texture of the beads were uniform before and after dissolution. The percentage of 
mosapride drug entrapment efficiency ranged from 97.4 ± 0.08 to 99.1 ± 0.04. The 
percentage of mosapride content from the beads was determined by high-
performance liquid chromatography (HPLC) and ranged from 97.9 ± 0.08 to 99.6 ± 
0.01.The in-vitro percentage release of mosapride from the beads at the end of 14 
hours ranged from 90.0 ± 0.2 to 99.5 ± 0.12. The formulated beads in formulations 1 
and 3 were sealed in vials and kept for 90 days at 40°C / 75% RH. After 90 days of 
exposure the percentage drug content was found to be 99.2 ± 0.04. The floating 
beads designed for the gastroretentive dosage form could be suitable for controlled 
drug delivery. 
15. Tanmoy Ghosh et al 24 studied different subcoats containing calcium 
chloride, citric acid or Eudragit E, respectively for immediate release theophylline 
pellets which were subsequently coated with shellac. Drug release from the resulting 
pellet formulations was measured. The mechanism of interaction between the 
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modifying subcoat ingredients and the shellac coating was investigated using FT-IR 
spectroscopy. All formulations with modifying subcoat prolonged drug release. 
Whereas the effect of calcium chloride was a result of ionic interactions with 
shellac, the effect of citric acid was a reduction of the degree of dissociation of 
shellac. The influence of Eudragit(®) E was  explained by the solubility 
characteristics of this basic polymer. The application of modifying subcoats was an 
easy and effective means to achieve sustained release from shellac-coated dosage 
forms. The choice of a suitable substance and the adjustment of its concentration 
allow tailor made sustained release profiles. 
16.  Sachin B Somwanshi et al 29 reviewed the multiparticulate drug delivery 
systems suitable for achieving sustained or delayed release oral formulations with 
low risk of dose dumping, flexibility of blending to attain different release patterns 
as well as reproducible and short gastric residence time. One of the approaches 
toward this goal was to develop the floating multiparticulates so as to increase the 
gastric retention time. Such systems have more advantages over the single-unit 
dosage forms. The development of floating multiparticulates involved different 
solvent evaporation techniques to create the hollow inner core. In this review, the 
current status of floating multiparticulate drug delivery systems including hollow 
microspheres (micro balloons), low density floating micro pellets and floating micro 
beads (acrylic resin based), microcapsules etc, their evaluation parameter, 
advantages, application, limitation and future potential for oral sustained release 
drug delivery were discussed.  
17. M. Thriveni et al 26 formulate and evaluated tizanidine hydrochloride 
sustained release pellets. Tizanidine hydrochloride is an immadazole α2-adrenergic 
agonist used in the management of increase in muscle tone associated with 
spasticity. It has short biological half-life of 2-2.5 h  and is rapidly eliminated from 
the body. Sustained release dosage form of Tizanidine hydrochloride was developed 
for reduction in total amount of dose administration, to improve patient compliance, 
and increase efficiency in the treatment. The pellets were prepared by pan coating 
and fluidized bed coating technique (Wurster type) using hydroxy propyl methyl 
cellulose E5 (HPMC E5), Ethyl cellulose N-50, Eudragit L-100 as polymers and 
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isopropyl alcohol, methylene dichloride as solvents. The pellets were filled in 
capsules and evaluated for weight variation, content uniformity, moisture content, 
lock length, disintegration and in-vitro dissolution tests and the results were found to 
be within the limits. A comparative study of dissolution profile of different batches 
with marketed product was performed.  The dissolution data was fitted with various 
kinetic models, and the optimized formulation followed zero order kinetics by non-
Fickian case-II diffusion process. Stability studies were conducted for 3 months 
according to ICH guidelines and found to have good results. 
18. Keerthi Kancharla et al 27 prepared and evaluated  multiparticulate 
floating drug delivery system of aceclofenac. The microspheres were prepared by 
emulsification solvent evaporation technique using Eudragit RS 100 as a release rate 
controlling polymer in the ratios 1:1, 1:2 and 1:3. The prepared microspheres were 
evaluated for drug-polymer compatibility, micromeritic properties, drug entrapment 
efficiency, in-vitro buoyancy and drug release studies. The mean particle size 
increased with increase in the polymer concentration, when compared to pure drug 
and it was lying between 14.71-25.93 µm. The micromeritic properties were found 
to be improved when compared to pure drug .Scanning electron microscopy 
confirmed the hollow structure with smooth external surface. The drug and polymer 
were found to be compatible as seen in IR studies. The entrapment efficiency 
considerably decreased with increase in the polymer concentration ranging from 78-
36 % respectively. The microspheres floated up to 12 h over the surface of the 
gastric buffer medium and the buoyancy percentage was found to be in the range of 
85-94%. In-vitro drug release studies showed that the prepared microspheres 
exhibited prolonged drug release for more than 12 hours. The mechanism of drug 
release was found to be a combination of both Peppas and zero order release 
kinetics. The developed floating microspheres of aceclofenac may be used for 
prolonged drug release for at least 12 h for maximizing the therapeutic efficacy 
along with patient compliance.  
19.  Neeta et al 28 prepared gastroretentive floating multiple-unit drug 
delivery system for glipizide as a model drug for prolongation of gastric residence 
time. Floating microspheres were prepared by ionotropic gelation method using 
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polymeric material such as chitosan. D-optimal design was utilized to investigate the 
joint influence of two variables: drug to polymer ratio (X1) and concentration of 
effervescent agent (X2) on the drug entrapment efficiency, percentage buoyancy, 
and cumulative percentage drug release. Particle size and surface morphology of 
prepared microspheres were characterized by optical and scanning electron 
microscopy respectively. Formulated microspheres exhibited prolonged drug release 
and remained buoyant for more than 12 h.  
20. Manas Tripathi et al 30   Formulated and evaluated the gastro-retentive 
floating microballoons of glipizide using hydrophilic polymers hydroxypropyl 
methylcellulose (HPMC) and Eudragit RS100 (RS 100) by emulsion solvent 
evaporation technique. The floating microballoons were evaluated using 
micromeritic properties,buoyancy, in vitro drug release, scanning electron 
microscopy and stability studies. The densities of floating microspheres (0.475-
0.975 g/cm3) were found to be less than the density of gastric fluid (1.004 g/cm3), 
therefore showed an extended floating time of more than 12 h over the gastric fluid. 
The entrapment efficiency of prepared floating microspheres was satisfactory 
(41.32-76.19%). The scanning electron microscopy confirmed the hollow nature of 
microspheres with pores on the surface which imparted floating properties to the 
prepared floating microballoons. Among all formulations, F4 (Drug:HPMC:RS 
100::1:4:3) was found to be the best as it exhibited highest drug release (99.12%) in 
12 h followed by diffusion mechanism and was stable for three months at ambient 
conditions. 
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 3. AIM AND OBJECTIVES 
 
3.1 Aim:  
 Glipizide is one of the most widely used oral hypoglycemic agents in the 
control of diabetes mellitus. It belongs to the class sulphonyl urea and is available as 
an immediate release tablet and controlled release tablet for once a day dosing. The 
innovator controlled release product of glipizide is glucotrol XL which is based on 
the osmotic drug delivery system is difficult to formulate and expensive to scale up 
since it involves investment in putting up a laser drill for drilling the hole required 
for the fluid to permeate into the system. 
 The current work is aimed at formulating a drug delivery system which 
will deliver the drug over 24 hours at the same rate of delivery as that of glucotrol 
XL but using the micro porous membrane drug delivery system and the multi unit 
particulate platform (MUPS). 
3.2 Objectives: 
(1) To standardize a procedure for loading drug on to non peril pellets. 
(2)  To determine the optimum level of ethyl cellulose needed to coat 
the pellets in order to get nearly zero order drug release from the 
pellets. 
(3)  To study the role of two different types of pore formers in 
modulating drug release to match to the target product profile. This 
study was conducted using full factorial design of experiments. 
 Page 26 
 4. DRUG PROFILE 
 
Drug  : Glipizide8 
Description : It is white odorless powder. 
Molecular structure: 
 
Molecular formula   : C21H27N5O4S 
Molecular weight     : 445.535 
 Solubility: Practically insoluble in water, sparingly soluble in acetone 
and soluble in ethylene chloride (Dichloromethane), chloroform and diethyl form 
amide. 
 Pka Value: Pka (strongest acidic) = 4.32 
 Pkb (strongest basic)=0.059 
 Category: Oral blood-glucose-lowering drug of the sulfonylurea class 
Anti-diabetic agent. 
Dose : 5-20 mg in once or twice daily. 
Half Life : 2-5 hours.  
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4.1           Mechanism of action2 : 
 Sulfonylurea’s likely  bind to ATP-sensitive potassium-channel receptors 
on the pancreatic cell surface, reducing potassium conductance and causing 
depolarization of the membrane. Depolarization stimulates calcium ion influx 
through voltage-sensitive calcium channels, raising intracellular concentrations of 
calcium ions, which induces the secretion, or exocytosis of insulin. 
4.2 Pharmacokinetics3: 
Absorption: Gastrointestinal absorption is uniform, rapid, and essentially complete. 
Distribution (protein binding):  98-99%, primarily to albumin. 
Metabolism: Hepatic. The major metabolites of glipizide are products of aromatic 
hydroxylation and have no hypoglycemic activity. A minor metabolite which 
accounts for less than 2% of a dose, an acetylaminoethylbenzene derivatives is 
reported to have 1/10 to 1/3 as much hypoglycemic activity as the parent compound. 
Elimination: 70 to 80% through urine. 
4.3 Doses8:  
 Dose: 5-20 mg in once or twice daily. 
 Administer glipizide in fixed combination with metformin once daily 
with a meal. 
 Individualize initial dosage of glipizide; usually 5–10 mg daily. The 
other oral antidiabetic agent may be discontinued abruptly.. 
 For more severe hyperglycemia (i.e., fasting plasma glucose 
concentrations of 280–320 mg/dl), 2.5 mg of glipizide and 500 mg of metformin 
hydrochloride twice daily. 
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 EXCIPIENT PROFILES 
4.4 Hydroxyl propyl methyl cellulose7 : 
Non-proprietary names : JP : Hydroxyl propyl methylcellulose 
   BP : Hypromellose 
   Ph Euro : Methyl hydroxyl propyl cellulosum 
   USP : Hypromellose 
Chemical Name : Cellulose, 2-hydroxypropyl methyl ether. 
Synonyms  : Methyl Hydroxyl Propyl Cellulose, Propylene Glycol 
   ether of methylcellulose, Mythical, Met lose, E464, 
   Pharmacia, Culminal MHPC. 
Structural Formula:  
OR
CH2OR
O
OO
O
O
OR
OR
OR
CH2OR
Where R is H, CH3 or CH3-CH(OH)-CH2  
Physical and chemical properties: 
Molecular weight : 10,000 – 15, 00,000 
Color  : White to creamy-white 
Nature  : Fibrous or granular powder 
Odor  : Odorless 
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Taste  : Tasteless 
Density  : 0.3-1.3 g/ml 
Specific gravity      : 1.26 
Solubility               : Soluble in cold water, practically insoluble                                            
      Chloroform, ethanol (95%) and ether but Soluble in                      
  mixture of ethanol and Dichloromethane. 
Viscosity      : HPMC 5cps, HPMC-K4M-3,000-5600mPas, K15M:                                
   12,000-21,000 maps, K100M: 80,000-1, 20,000 maps. 
Melting point : Browns at 190-200°C, chars at 225-230°C, Glass                                                                                     
       transition temperature is 170-180°C. 
Functional category : Coating agent, film-forming, rate-controlling polymer for 
sustained release, stabilizing agent, suspending agent, 
tablet binder, viscosity-increasing agent. 
Stability & storage : Stored in an air-tight container in a cool and dry place.           
   It is stable although it is slightly hygroscopic. 
4.5.1 Applications:   
 In oral product HPMC is primarily used as tablet binder, in film 
coating and as an extended release tablet matrix. Concentration 
between 2-5% w/w may be used as a binder in either wet or dry 
granulation process. High viscosity grade may be used to retard the 
release of water-soluble drug from a matrix. 
 HPMC is used as an adhesive in plastic bandage and as a wetting 
agent for hard contact lenses. It is widely used in cosmetics and 
food products. In addition, HPMC is used as an emulsifier, 
suspending agent and stabilizing agent in topical gels and 
ointments. As a protective colloid, it can prevent droplets and 
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particle from coalescing or agglomerating thus, inhibiting the 
formation of sediments. 
4.5.3 Polyethylene Glycol5: 
 
Molecular formula  : C18 H38 O10. 
Molar mass          : 380-420 gm/mol. 
Density              : 1.128g/cm3 
Melting point       : 4-8 0oc 
Viscosity           : 90 cst at 250c, 7.3 cst at 99 0c  
 PEG-4000 is low molecular weight grade of PEG. It is clean, colorless. 
viscous liquid, due in part to its low toxicity. PEG-4000 is widely used in variety of 
pharmaceutical  formulation . more recently, it has been used to make” E-liquid” for 
electronic cigarettes (personnel vaporizers). 
Chemical Properties: 
 PEG-4000 strongly hydrophilic. The partition-coefficient of PEG-4000 
between hexane and water is 0.000015(log=-4.8),indicating that when PEG-4000 is 
mixed with water and hexane there are only 15 parts of PEG-400 in the hexane layer 
per 1 million parts of PEG-400 in the water layer. 
 PEG-400 is soluble in water, acetone, alcohols, benzene, glycerin, glycol 
and aromatic carbons and is slightly soluble in aliphatic hydrocarbons. 
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4.5.4 Polyvinyl pyrrolidone6: 
 Polyvinyl pyrrolidone (PVP), also commonly called  Polyvidone or 
Povidone, is a water-soluble polymer made from the monomer N-vinylpyrrolidone:  
 
Properties: 
 PVP is soluble in water and other polar solvents. When dry it is a light 
flaky hygroscopic powder, readily absorbing up to 40% of its weight in atmospheric 
water. In solution, it has excellent wetting properties and readily forms films. This 
makes it good as a coating or an additive to coatings. 
4.5.5  Uses: 
 It is used as a binder in many pharmaceutical tablets. It simply passes 
through the body when taken orally. 
 PVP added to iodine forms a complex called providence-iodine that 
possesses disinfectant properties. This complex is used in various products like 
solutions, ointment, pessaries, liquid soaps and surgical scrubs. 
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                                        4. PLAN OF WORK 
  
 Literature survey 
 Analytical method development.  
 Pre formulation studies 
 Drug and excipient profile. 
 Base coated Drug loading to pellets (FBC). 
 Assay of drug coated pellets. 
 Functional coating (FBC).               
 Evaluation of  final coated pellets 
• Dissolution studies using   pH-7.2 phosphate buffer. 
• DOE 
 Stability studies 
 Results and discussion  
 
 6. MATERIALS AND METHODS 
 
6.1  Table No 1: List of materials /excipients /chemicals 
Chemical Manufacturer/supplier 
Glipizide Emcoind , Hyderabad 
Isopropyl alcohol Merck India 
HPMC 5cps Dow Chemicals 
Dichloromethane Luzenac, U.S 
Ethylcellulose Evonik Industries 
Polyvinylpyrrolidone Evonik  Industries 
PEG-400 Merck India 
 
6.2  Table No 2: List of equipments 
Name of equipment Make 
Fluid Bed Processor Gansons 
Mechanical Stirrer Remi  Motors 
Uv-Visible Spectrophotometer Shimadzu 
Friability Tester Electro Lab 
Dissolution Tester Electro Lab 
Digital Balance Mettler Toledo 
Weighing Balance 5 Kg Mettler Toledo 
Weighing Balance 10 Kg Mettler Toledo 
Mechanicalsieve Stirrer Remi Motors 
pH Meter Elico Ltd 
Stability Chamber Thermo Lab 
Tap Density Tester Electro Lab 
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6.3 Formulation development10: 
Glipizide controlled  release pellets : 
 In this work, the method used for preparing Glipizide layered release 
pellets was solution/suspension- layering technique. 
 The three main steps followed in solution/suspension layering technique 
to prepare controlled release pellets of Glipizide were, 
i.  Drug loading. 
ii.   Seal coating. 
iii.  Functional coating. 
6.3.1 Drug loading:  
 2 g of glipizide was taken in a beaker and  35 ml of isopropyl alcohol and  
15 ml dichloromethane was added. The contents were mixed thoroughly by using 
mechanical stirrer. Then the drug solution was sprayed onto non-pareil sugar seeds 
(25 g) by using fluidized bed-dryer technique.  
6.3.2 Seal coating: 
 5 g of  HPMC was taken in beaker and 35 ml of isopropyl alcohol and  15 
ml dichloromethane was added. The contents were mixed thoroughly by using 
mechanical stirrer.  During stirring 0.5 ml of   PEG-400 was added drop by drop to 
the solution. Then the seal coated solution was sprayed onto sugar seeds drug loaded 
pellets using fluidized bed-dryer technique.  
6.3.3 Functional coating: 
 The functional coating was done using ethyl cellulose and using two pore 
formers namely, PEG 4000 and PVP.   
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Functional coating plays most important role in controlling drug release.  
The first type of functional coating is as given below. 
1. Composition of functional coating on are given in Table No. 3.  
Ethyl cellulose and PEG-400 was taken in beaker and 
dichloromethane was added.  The contents were mixed thoroughly 
by using mechanical stirrer.  Then the coating solution was sprayed 
onto seal coated pellets by using fluidized bed-dryer technique. 
 The second type of functional coating with PEG 4000 as pore former is 
as given below.  
2. Composition of functional coating is given in Table No. 4.  Ethyl 
cellulose and PEG-4000 were taken in beaker and dichloromethane 
was added.  The contents were mixed thoroughly by using 
mechanical stirrer and during stirring PEG-400 were added drop by 
drop to the solution. Then the coating solution was sprayed onto seal 
coated pellets by using fluidized bed-dryer technique. 
The third type of functional coating with PVP as pore former is as given below.  
3. Composition of functional coating is given in Table No. 5.  Ethyl 
cellulose and PVP were taken in beaker and dichloromethane was 
added.  The contents were mixed thoroughly by using mechanical 
stirrer and during stirring PEG-400 were added drop by drop to the 
solution. Then the coating solution was sprayed onto seal coated 
pellets by using fluidized bed-dryer technique. 
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Table No 3: Composition of glipizide pellets using ethyl cellulose: 
Ingredients F1 
Non-pariel sugar seeds (g) 25 
Glipizide (g) 2 
HPMC 5cps (g) 5 
Isopropyl alcohol (ml) 70 
Dichloromethane (ml) 130 
PEG-400 (ml) 1 
Ethyl cellulose (g) 10 
 
Table No 4: Composition of glipizide pellets using PEG – 4000 as pore former: 
Ingredients 
F2 F3 F4 F5 F6 F7 F8 F9 F10 
LL LM LH ML MM MH HL HM HH 
Non-pariel sugar 
seeds (g) 
25 25 25 25 25 25 25 25 25 
Glipizide (g) 2 2 2 2 2 2 2 2 2 
HPMC 5cps (g) 5 5 5 5 5 5 5 5 5 
Isopropyl alcohol 
(ml) 
70 70 70 70 70 70 70 70 70 
Dichloromethane 
(ml) 
130 130 130 130 130 130 130 130 130 
PEG-400 (ml) 1 1 1 1 1 1 1 1 1 
PEG-4000 (g) 5 5 5 10 10 10 15 15 15 
Ethyl cellulose (g) 15 20 25 15 20 25 15 20 25 
 
 
 
 Page 37 
Table No 5: Composition of glipizide pellets using PVP as pore former: 
Ingredients 
F11 F12 F13 F14 F15 F16 F17 F18 F19 
LL LM LH ML MM MH HL HM HH 
Non-pariel sugar seeds (g) 25 25 25 25 25 25 25 25 25 
Glipizide (g) 2 2 2 2 2 2 2 2 2 
HPMC 5cps (g) 5 5 5 5 5 5 5 5 5 
Isopropyl alcohol (ml) 70 70 70 70 70 70 70 70 70 
Dichloromethane (ml) 130 130 130 130 130 130 130 130 130 
PEG-400 (ml) 1 1 1 1 1 1 1 1 1 
PVP (g) 5 5 5 10 10 10 15 15 15 
Ethyl cellulose (g) 15 20 25 15 20 25 15 20 25 
 
6.4  Analytical methods: 
6.4.1 Preparation of glipizide standard stock solution in phosphate buffer 
solution 
PH 7.2: 
 A standard stock solution of  glipizide  was prepared by dissolving 
accurately weighed 100 mg of glipizide with 10 ml of methanol and the volume was 
made up to 100 ml in volumetric flask with phosphate buffer , pH 7.2 to obtain a 
stock solution of 1000 µg /ml. 
6.4.2 Determination of analytical wavelength: 
 From the standard stock solution, 1ml was pipette out into 100 ml 
volumetric flask. The volume was made up to 100 ml with phosphate buffer, pH 7.2 
and the resulting solution containing 10 µg /ml was scanned between 200 and 400 nm 
using  Schimadzu UV-1601 UV-Visible Spectrophotometer.  The λmax was found to 
be 226 nm. 
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6.4.3 Calibration curve of glipizide in Ph 7.2 Buffer: 
 Accurately weighed quantity of glipizide (100 mg) was dissolved in little 
quantity of pH 7.2 phosphate buffer solution and volume was made up to 100 ml. 
From this, 5 ml of solution was pipette out into a volumetric flask and volume was 
made up to 50 ml. Appropriate  aliquots were taken ( 0.2, 0.5, 1, 1.5, 2 ml) into 
different volumetric flasks and volume was made up to 10 ml with pH 7.2  buffer so 
as to get drug concentrations of 2, 5, 10, 15, to 20 µg/ml. The absorbance of these 
drug solutions were estimated at 226 nm in Schimadzu UV-1601 UV-Visible 
Spectrophotometer. This procedure was performed in triplicate to validate the 
calibration curve.   
6.5 Evaluation of glipizide pellets: 
6.5.1 Assay of glipizide 31: 
 100 mg of drug loaded pellets were taken in 100 ml volumetric flask. To 
this  required  quantity of  methanol was added and placed in sonicater to dissolve the 
pellets. Then volume was make up to 100 ml using pH 7.2 phosphate buffer. The 
solution was filtered, from this 1ml was pipetted out and the volume was made 
upto10 ml using pH 7.2 phosphate buffer.   The absorbance was measured at 226 nm. 
6.5.2 Dissolution of glipizide pellets in 7.2 phosphate buffer 31: 
Apparatus  : USP-I basket apparatus. 
RPM           : 100    
Temperature : 37 ± 0.50 C  
Wave length  : 226 nm 
Procedure: 
 900 ml of the dissolution medium was placed in the dissolution  
apparatus and temperature was equilibrated to  37±0.50C  .  The sample equivalent to 
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5  mg of glipizide pellets was placed in the basket of the dissolution apparatus and 
rotated at 100 rpm. At regular time intervals 5 ml of the dissolution medium was 
withdrawn, and replaced with the buffer. The  absorbance was measured at 226 nm 
in Schimadzu UV-1601 UV-Visible Spectrophotometer.  In order to understand the 
mechanism and kinetics of drug release, the results of the in vitro drug release study 
were fitted with various kinetic equations like zero order (% release vs. t), first order 
(log % release vs. t) and Higuchi model (Mt/M∞vs. t1/2). In order to define a model 
which would represent a better fit for the formulation, drug release data was further 
analyzed by Peppas equation, Mt/M∞=ktn, where Mt is the amount of drug released 
at time t and M∞ is the amount released at time ∞, thus the Mt/M∞ is the fraction of 
drug released at time t, k is the kinetic constant and n is the diffusional exponent, a 
measure of the primary mechanism of drug release. R2 values were calculated for the 
linear curves obtained by regression analysis of the above plots.   
 
Fig 9. SP-I basket EI apparatus 
6.6  Stability studies31: 
 The stability studies on formulation scale up batch were carried out 
according to ICH guidelines. The design and execution of the stability study 
followed the principles outlined in the ICH parent guidelines.  The purpose of the 
study was to establish, a retest period or shelf life and label storage instructions 
applicable to all future batches manufactured and packaged under similar conditions. 
The glipizide pellets were filled in capsules and were stored in clean, dry, moisture 
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proof bottles.  They were stored in air tight containers and placed in the humidity 
chamber at 40oC ± 2oC/75% ± 5% RH. The accelerated studies were carried out for 
three months and the testing frequency was at 0, 1, 2 and 3 months.  The 
recommended storage condition for Climatic Zone IV was followed which was 
40oC±2oC/75% ± 5% RH. The attributes tested were assay and dissolution study. 
The following were considered as significant change 
• A 5% change in assay from initial value 
• Failure to meet acceptance criteria for appearance, physical 
attributes and functionality test. 
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 7. RESULTS AND DISCUSSION 
 
7.1 Calibration curve of glipizide: 
 The values for the absorbance at different concentration are shown in 
Table No 6 and Fig.10.  The calibration curve constructed for samples covered a 
range of concentrations from 2 to 20 µg/ml and was found to be linear with a linear 
regression coefficient value of 0.998. 
Table No 6: Calibration curve of glipizide 
Concentration (µg/ml) Absorbance 
0 0 
2 0.102 
5 0.256 
10 0.512 
15 0.768 
20 0.978 
 
 
Fig 10. Calibration curve of glipizide 
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7.2 Assay: 
 The drug content determined was found to be as shown in Table No 7-9. 
Table No 7: Assay of formulation F1 
Formulation % drug content 
F1 93.2 
 
Table No 8: Assay of formulation F2-F10 
Formulation % drug content 
F2 96.3 
F3 94.2 
F4 94.6 
F5 98.2 
F6 94.0 
F7 96.1 
F8 92.7 
F9 96.8 
F10 95.7 
 
Table No 9: Assay of formulation F11-F19 
Formulation % drug content 
F11 94.3 
F12 98.2 
F13 96.3 
F14 96.7 
F15 98.2 
F16 97.5 
F17 96.9 
F18 98.1 
F19 99.1 
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7.3 Dissolution parameters of glipizide pellets : 
 The results of the dissolution profile of the prepared pellets are shown in 
Table No 10-13. and represented graphically in Fig.11-13. 
 The minimum weight gain required for ethyl cellulose coating onto drug 
loaded pellets required to seal the pellets was 30 % w/w. Hence all experiments with 
pore former were conducted at 30% weight gain. 
 In case of formulation F1, different thickness of coating was applied.  As 
the percentage of coating increased the rate of dissolution decreased. 
 When PEG 4000 was used as pore former, formulation with 
medium/lower that is medium level of  ethyl cellulose (20%), low level of PEG (5%) 
(formulation F5) alone was able to give dissolution profile matching to the target 
product profiles. 
 When PVP was used as pore former only medium/low and high/medium 
(formulation F14) were matching to the target product profile. 
 Both PEG 4000 and PVP can be effectively used as pore formers.
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 Table No 10: Dissolution profile of glipizide pellets using ethyl cellulose 
Time 
(in hrs) 
Ethyl cellulose (%weight gain) 
F1 
 5% 10% 15% 20% 25% 30% 35% 40% 
O 0 0 0 0 0 0 0 0 
2 25.48±5.3 10.09±4.2 7.08±2.1 8.78±1.0 2.98±2.55 0 0 0 
4 56.09±2.3 44.28±3.6 16.88±5.2 22.76±5.8 4.07±0.1 3.68±1.5 0 0 
8 88.09±3.6 65.78±4.1 37.89±2.8 30.09±5.6 10.76±0.8 9.76±1.2 2.45±1.5 0 
12 90.26±2.6 82.27±5.3 46.67±6.3 35.77±7.2 12.85±5.2 10.54±2.4 5.76±4.2 1.54±1.2 
16 92.17±2.6 90.08±3.3 60.98±0.9 42.56±1.5 22.65±2.6 20.44±3.6 8.97±4.5 3.07±0.6 
24 98.09±2.1 92.09±4.2 74.78±3.2 55.88±2.5 30.28±2.5 30.77±3.2 10.09±1.5 5.48±5.3 
 Page 45 
  
 
Fig 11. Dissolution profile of glipizide pellets using ethyl cellulose 
 
Table No 11: Concentration of polymers used coating 
POLYMER 
CONCENTRATION (%) 
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 Table No 12: Dissolution profile of Glipizide pellets using polyethylene glycol-4000 
Time  
(in hrs) 
TPP F2 F3 F4 F5 F6 F7 F8 F9 F10 
 Low High LL LM LH ML MM MH HL HM HH 
0 0 0 0 0 0 0 0 0 0 0 0 
2 0 5 7.54±1.3 12.45±2.3 27.09±3.3 4.23±4.1 5.87±1.5 14.32±3.2 0 0.37±1.2 3.29±0.9 
4 10 30 28.87±2.1 38.45±3.2 54.98±5.2 17.89±6.3 20.61±1.2 29.45±0.6 1.29±2.1 7.58±3.2 12.76±1.2 
8 25 55 30.79±2.3 62.67±3.2 67.78±1.8 28.44±5.2 37.45±3.2 43.08±4.2 5.35±2.6 13.49±3.6 25.48±2.1 
12 50 75 55.32±2.1 75.34±2.1 80.97±3.2 53.87±1.2 62.07±3.4 78.12±0.9 14.48±2.3 26.55±2.3 44.07±0.8 
16 65 85 75.29±1.2 84.35±5.2 85.67±3.1 72.64±5.1 68.34±1.2 80.16±1.21 34.08±5.1 42.78±6.1 67.57±2.1 
24 80 100 84.28±2.6 87.28±1.4 87.54±2.5 83.24±0.9 85.28±5.6 87.54±2.6 55.87±4.3 66.08±5.0 78.09±0.9 
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Fig 12. Dissolution profile of Glipizide pellets using polyethyleneglycol-4000
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 Table No 13: Dissolution profile of glipizide pellets using PVP 
Time  
(in hrs) 
TPP F11 F12 F13 F14 F15 F16 F17 F18 F19 
 Low High LL LM LH ML MM MH HL HM HH 
O 0 0 0 0 0 0 0 0 0 0 0 
2 0 5 10.35±1.2 20.23±1.4 37±2.4 3.23±2.3 9.87±3.4 24.32±4.5 2.32±2.4 3.54±3.5 9.29±3.8 
4 10 30 41.87±1.4 58.45±2.4 74.98±3.6 27.89±3.4 25.61±3.8 39.45±4.4 5.29±2.8 12.58±3.6 22.76±3.5 
8 25 55 44.79±1.8 72.67±2.5 87.78±3.5 38.44±3.5 47.45±3.6 48.76±3.5 10.35±4.5 23.49±4.6 65.48±2.5 
12 50 75 65.32±1 85.34±2.7 90.97±3.6 63.87±2.6 80.26±2.6 88.12±2.4 28.44±2.6 66.48±3.5 72.56±3.8 
16 65 85 85.29±1.1 94.35±4.2 95.67±4.5 82.64±3.5 88.23±2.4 98.50±2.9 42.48±3.8 82.64±2.6 86.57±1.6 
24 80 100 100±1.5 97.28±3.5 96.54±3.4 90.24±1.4 93.09±4.4 99.26±3.0 75.08±4.6 96.78±3.7 90.45±1.9 
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 Fig 13. Dissolution profile of Glipizide pellets using polyvinylpyrrolidone 
7.4 Release kinetics:  
 Different kinetic models (zero-order, first-order, Higuchi’s, Korsmeyer’s 
and Hixson Crowell) were applied to interpret the release profile (the order and 
mechanism of glipizide release) from the pellets as shown in Table No 14-16 and 
Fig.14-16. To study the mechanism of drug release from the pellets, the release data 
were fitted to zero-order, first-order, and Higuchi equation. However, two factors 
diminish the applicability of Higuchi’s equation to matrix systems. This model fails 
to allow the influence of swelling of the matrix (upon hydration) and gradual erosion 
of the matrix. Therefore, the dissolution data were also fitted according to the well-
known exponential equation (Korsmeyer Peppas equation), Eq. (1), which is often 
used to describe the drug release behavior from polymeric systems. 
 Log (Mt /Mf) = Log k + n Log t --15------------ (1) 
where, Mt is the amount of drug release at time t; Mf is the amount of drug release 
after infinite time; k is a release rate constant incorporating structural and geometric 
characteristics of the tablet; and n is the diffusional exponent indicative of the 
mechanism of drug release. 
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(1) Zero, Higuchi , first order  kinetics indicates  the order of release  of 
drug i.e. the release is  dependent on time (first)/square root of time 
(Higuchi)/independent of time (Zero). 
(2)  Peppas model indicating the mechanism of drug release i.e, release 
of drug from the formulation is by diffusion, erosion, swelling and 
may by the combination of diffusion and swelling. 
(3)  Hixson Crowell model indicates that the release of drug is by 
dissolution. 
(4) The values obtained for 24 hrs are indicated by the regression co-
efficient values of the respective kinetic models and the graphs are 
also plotted in the individual charts. 
(5) Greater the regression coefficient greater the linearity towards the 
kinetic model. 
 Criterion of selecting the most appropriate model was based on the best 
goodness of fit. The values of the kinetic rate constant (k) and correlation coefficient 
(R2) as calculated from equations are presented in Table No 14-16. 
 Generally speaking, the ± majority of formulations did not seem to 
follow a zero order profile of drug release based on the lower R2 values obtained 
compared to the other kinetic models examined. On the other hand, the R2 values 
obtained from examining the first order and the Hixson-Crowell models were found 
to be very close to each for the formulations investigated. Nevertheless the R2 values 
for Hixson-Crowell model were slightly higher than the other models, showing a 
better conformance to this model.  The release of drug was predominantly by 
dissolution. 
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 Table No 14: Kinetic evaluation of drug release data of medium/lower 
concentration of PEG-4000 as pore former 
 
 
 
RELEASE KINETICS 
ZERO HIGUCHI PEPPAS FIRST ORDER 
HIXSON 
CROWELL 
Slope 3.792 19.053 1.1876 0.0095 0.0942 
R2 0.9272 0.9137 0.9547 0.9846 0.9866 
 
 
 
Fig 14. Drug release data of medium/lower concentration of PEG-4000 
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 Table No 15: Kinetic evaluation of drug release data of medium/lower 
concentration of PVP as pore former 
 
 
 
RELEASE KINETICS 
ZERO HIGUCHI PEPPAS FIRST 
HIXSON 
CROWELL 
Slope 4.094 21.080 1.257 0.010 0.113 
R2 0.9269 0.9291 0.9582 0.9838 0.9882 
 
 
 
Fig 15. Drug release data of medium/lower concentration of PVP 
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 Table No 16: Kinetic evaluation of drug release data of higher/medium 
concentration of PVP as pore former 
 
 
RELEASE KINETICS 
ZERO HIGUCHI PEPPAS FIRST HIXSON 
CROWELL 
Slope 4.559 22.515 1.383 0.013 0.140 
      
R2 0.9396 0.8663 0.9687 0.9837 0.9961 
 
 
 
Fig 16. Drug release data of higher/medium concentration of PVP 
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7.5 Design of experiment: 
 The conduct of an experiment and the subsequent interpretation of its 
experimental outcome are the twin essential features of the general scientific 
methodology. This can be accomplished only if the experiments are carried out in a 
systematic way and the inferences are drawn accordingly. The theme of the DOE 
optimization methodology provides thought-through and thorough information on 
diverse DOE aspects organized in a seven-step sequence 
 The optimization study begins with Step I, where an endeavor is made to 
ascertain the initial drug delivery objective(s) in an explicit manner. Various main 
response parameters, which closely and pragmatically epitomize the objective(s), are 
chosen for the purpose. In Step II, the experimenter has several potential 
independent product and/or process variables to choose from. By executing a set of 
suitable screening techniques and designs, the formulator selects the vital few 
influential factors among the possible “so many” input variables. Before going to the 
more detailed study, experimental studies are undertaken to define the broad range 
of factor levels as well. During Step III, an apposite experimental design is worked 
out on the basis of the study objective(s), and the number and the type of factors, 
factor levels, and responses being explored. Working details on variegated vistas of 
the experimental designs, customarily required to implement the DOE optimization 
of drug delivery, have been elucidated in the subsequent section. Afterward, the 
response surface methodology (RSM) is characteristically employed to relate a 
response variable to the levels of input variables, and a design matrix is generated to 
guide the drug delivery scientist to choose optimal formulations. In Step IV, the 
drug delivery formulations are experimentally prepared according to the approved 
experimental design, and the chosen responses are evaluated. Later in Step V, a 
suitable mathematical model for the objective(s) under exploration is proposed, the 
experimental data thus obtained are analyzed accordingly, and the statistical 
significance of the proposed model discerned. Optimal formulation compositions are 
searched within the experimental domain, employing graphical or numerical 
techniques. This entire exercise is invariably executed with the help of pertinent 
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computer software. Step VI is the penultimate phase of the optimization exercise, 
involving the validation of the response prognostic ability of the model put forward. 
 The drug delivery performance of some studies, taken as the checkpoints, 
is assessed vis-à-vis that is predicted using RSM, and the results are critically 
compared. Finally, during Step VII, which is carried out in the industrial milieu, the 
process is scaled up and set forth ultimately for the production cycle. 
The dissolution values at 2 hrs, 8 hrs and 24 hrs were fed into the DOE pro-excel 
software surface plots and interaction plots are shown in Fig.17-28 and  
Table No 17-24.   
Table No 17: Design of experiment for 2 hrs 
Formulation 
Polymers 
% drug release 
Ethyl cellulose PEG-4000 
F2 15 5 7.54 
F3 15 10 12.45 
F4 15 15 27.09 
F5 20 5 4.23 
F6 20 10 5.87 
F7 20 15 14.32 
F8 25 5 0 
F9 25 10 0.37 
F10 25 15 3.29 
  
 Page 56 
 Fig 17. Interaction plot of 2 hrs 
 
Fig 18. Surface plot of 2 hrs 
Table No 18: Design of experiment for 8 hrs 
Formulation 
Polymers 
% drug release 
Ethyl cellulose PEG-4000 
F2 15 5 30.79 
F3 15 10 62.67 
F4 15 15 67.78 
F5 20 5 28.44 
F6 20 10 37.45 
F7 20 15 43.08 
F8 25 5 5.35 
F9 25 10 13.49 
F10 25 15 25.48 
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 Fig 19. Interaction plot of 8 hrs 
 
Fig 20. Surface plot of 8 hrs 
Table No 19: Design of experiment for 24 hrs 
Formulation 
Polymers 
% drug release 
Ethylcellulose PEG-4000 
F2 15 5 84.28 
F3 15 10 87.28 
F4 15 15 87.54 
F5 20 5 83.24 
F6 20 10 85.28 
F7 20 15 87.54 
F8 25 5 55.87 
F9 25 10 66.08 
F10 25 15 78.09 
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 Fig 21. Interaction plot of 24 hrs 
 
Fig 22. Surface plot of 24 hrs 
Table No 20: Design space for glipizide controlled release pellets coated with 
ethyl cellulose using PEG- 4000 as pore former 9 
INGREDIENTS LOW MEDIUM HIGH 
Ethyl cellulose 19 20 21 
Polyethylene glycol 13.8 14.2 14.5 
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Table No 21: Design of experiment for 2 hrs 
Formulation 
Polymers 
% drug release 
Ethyl cellulose Polyvinyl pyrrolidone 
F11 15 5 10.35 
F12 15 10 20.23 
F13 15 15 37 
F14 20 5 3.23 
F15 20 10 9.87 
F16 20 15 24.32 
F17 25 5 2.32 
F18 25 10 3.54 
F19 25 15 9.29 
 
 
Fig 23. Interaction plot of 2 hrs 
 
Fig 24. Surface plot of 2 hrs 
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Table No 22: Design of experiment for 8 hrs 
Formulation 
Polymers 
% drug release 
Ethyl cellulose PVP 
F11 15 5 44.79 
F12 15 10 72.67 
F13 15 15 87.78 
F14 20 5 38.44 
F15 20 10 47.45 
F16 20 15 48.76 
F17 25 5 10.35 
F18 25 10 23.49 
F19 25 15 65.48 
  
 
Fig 25. Interaction plot of 8 hrs 
 
Fig 26. Surface plot of 8 hrs 
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Table No 23: Design of experiment for 24 hrs 
Formulation Polymers % drug release 
Ethyl cellulose PVP 
F11 15 5 100 
F12 15 10 97.28 
F13 15 15 96.54 
F14 20 5 90.24 
F15 20 10 93.09 
F16 20 15 99.26 
F17 25 5 75.08 
F18 25 10 96.78 
F19 25 15 90.45 
 
 
Fig 27. Interaction plot of 24 hrs 
 
Fig 28. Surface plot of 24 hrs 
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Table No 24: Design space for glipizide controlled release pellets coated with 
ethyl cellulose using polyvinyl pyrrolidone as pore former 9 
INGREDIENTS LOW MEDIUM HIGH 
Ethyl cellulose 18 21 22 
Polyvinyl pyrrolidone 6.6 9 11.67 
 
7.6 Stability testing: 
 The following were considered as significant change 
 The stability studies were carried out according to ICH guidelines. The 
design and execution of the stability study followed the principles outlined in the 
ICH parent guidelines.  The purpose of the study was to establish, based on testing a 
retest period or shelf life and label storage instructions applicable to all future 
batches manufactured and packaged under similar conditions. They were stored in 
air tight containers and placed in the humidity chamber at 40oC ± 2oC/75% ± 5% 
RH. The accelerated studies were carried out for three months and the testing 
frequency was at 0, 1, 2 and 3 months.  The recommended storage condition for 
Climatic Zone IV was followed which was 40oC ± 2oC/75% ± 5% RH. The 
attributes tested were assay and dissolution profile.  The real time study was done at 
25°C± 2oC /65% ± 5% RH. 
• A 5% change in assay from initial value 
• Failure to meet acceptance criteria for assay and dissolution profile.  The 
guidance and recommendations detailed in the ICH guidelines to propose a retest or 
shelf life was followed.  The scale up batch was fabricated by using the fluid bed 
processor as described previously, filled into size ‘2’ hard gelatin capsules shells and 
subjected to evaluation for assay and dissolution profile testing. Capsules were filled 
in 90 cc white HDPE containers at 30 s count per container and loaded on to 
accelerated and real time stability study. The samples were withdrawn at 1, 2 and 3 
months from the accelerated stability chamber and at 3 months from the real time 
stability chamber and subjected to evaluation. The batches selected for the stability 
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testing contained 100% of the label claim. The stability information presented 
includes results from physical, chemical and release profile tests. The attributes 
tested were assay and dissolution profile.  Each attribute was assessed separately. 
The results are shown in Table No 25 and 26. 
Table No 25: Formula for the scale up and reproducibility batch 
S.No Ingredient Specification Quantity 
1 Non-pariel sugar seeds (g) USP 61.5 
2 Dichloromethane (ml) USP 300 
3 IPA (ml) USP 700 
4 Glipizide (g) USP 15 
5 HPMC 5cps (g) USP 5 
6 PEG – 400 (ml) USP 1.0 
7 ETHYL CELLULOSE (g) USP 20 
8 PVP K30 (g) USP 7.5 
9 Hard gelatin capsules shells size ‘2’  1 
 
Table No 26: 
S.NO TIME (IN MONTHS) 
 
At 40°C/ 75% RH 25°C/65% RH 
0 1 month 2 months 3 months 3 months 
Assay (% drug content)  
(95% to 105%) 100.09 99.97 98.74 97.49 98.93 
TARGET PRODUCT 
PROFILE  
 
   
 
TIME (H) Mean % drug released  
 
   
0 0 0 0 0 0 0 
2 0-5 3.54 3.87 4.02 4.09 4.17 
4 10-30 12.58 10.74 19.41 19.27 10.13 
8 25-55 32.49 28.78 33.45 35.78 30.87 
16 65-85 72.64 79.76 75.17 81.21 77.33 
24 80-100 96.78 98.76 97.06 99.17 98.54 
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The F optimized formula was scaled up to 1000 Capsules. 
• The pellets were filled in “2“size. 
• Capsules were filled in HDPE containers and the cap was induction 
sealed. 
• The containers were incubated at 25°C/ 65% RH and 40 ºC /75% 
RH. 
• The samples were withdrawn at 1M, 2M and 3M time intervals for 
40°C/ 75% RH and 3M for 25°C/ 65% RH and analyzed for % drug 
content. 
• The data is compiled and compared with the initial values for % 
drug content and dissolution profile and found that the results are 
within the acceptable limits. 
Assay: 
 The assay of the pellets selected and filled in capsules was determined 
individually at time intervals of 0, 1, 2 and 3 months.   The assay was found to be 
97.49 % at the end of 3 months.  The dissolution profile matched the TPP till the end 
of 3 months.  In case of real time study the assay at the end of 3 months was found 
to be 98.93 % and the dissolution profile matched the TPP till the end of 3 months. 
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 8. SUMMARY AND CONCLUSION 
 
 Glipizide controlled release formulation is one of the most widely 
prescribed oral hypoglycemic agent. The innovator for product Glucotrol XL is 
based on the osmotic drug delivery platform and has a very peculiar dissolution 
profile. There is a two hours lag time in which less than 5% of the drug is targeted to 
be release followed by a zero order drug release at a rate of 3 to 7 % per hour.  
Ordinary matrix diffusion systems are very difficult to formulate for such type of 
specialized release rate requirements since these systems are based mainly on 
diffusion across swollen matrix. 
 The MUPS technology provides a unique platform to modulate the drug 
release to match the target release profile since it is possible to coat the pellets in a 
controlled manner with an polymer and a pore former. 
 In the current work, Glipizide controlled release product was developed 
using the MUPS platform, and ethyl cellulose as the membrane. The role of two 
water soluble polymers in modulating the drug release was evaluated using full 
factorial design of experiments. 
 The process followed for fabricating the dosage form was by first loading 
the drug on to pellets by using the fluid bed processor attached with bottom spray 
assembly. These pellets were then coated with either of the following: 
(1)  Ethyl cellulose: Weight gain 5% to 30%. This study was conducted 
to establish the level of coating required to completely seal the drug 
release. At 30% weight gain, the drug release was low over 24 
hours. 
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(2)  All further coatings were conducted up to 30% weight gain of the 
polymer. 
(3)  Full factorial 32 design of experiments was conducted by varying 
the levels of EC and PEG 4000 as pore former. The dissolution 
profile was conducted for all 9 batches and the values at 2, 8 and 24 
hours were fed into DOE Pro XL software. The design space 
achieved was as given in below Table No 27. 
Table No 27: Design space of PEG-4000 
INGREDIENTS LOW MEDIUM HIGH 
Ethyl cellulose 19 20 21 
Polyethyleneglycol4000 13.8 14.2 14.5 
 
(4) Full factorial 32 design of experiments was conducted by varying 
the levels of EC and PVP as pore former. The dissolution profile 
was conducted for all 9 batches and the values at 2, 8 and 24 hours 
were fed into DOE Pro XL software. The design space achieved 
was as given in below Table No 28. 
Table No 28: Design space of PVP 
INGREDIENTS LOW MEDIUM HIGH 
Ethyl cellulose 18 21 22 
Polyvinylpyrrolidone 6.6 9 11.67 
 
(5)  Based on the DOE experiments, it was established that PVP is a 
better pore former for Glipizide controlled release pellets as 
compared to PEG 4000. This may be due the fact that PVP acts as a 
solubilizer for the practically insoluble Glipizide. 
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(6)  A reproducibility batch of 100 gram pellets was taken in which the 
drug loaded pellets were coated with 20% EC and 7.5% PVP . 
(7)  The pellets were filled in size ‘2’ hard gelatin capsules shells and 
subjected to accelerated stability studies for 3 months. 
(8)  The reproducibility and stability experiments indicate that it is 
possible to develop a controlled release product of Glipizide using 
the micro porous film platform and the MUPS platform with the 
product matching to the target product profile and having excellent 
reproducibility and stability. 
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